The Oncology Drugs Market size was USD 221.38 Billion in 2023 and is expected to Reach USD 525.08 Billion by 2031 and grow at a CAGR of 11.4% over the forecast period of 2024-2031.
The Oncology Drugs Market refers to the pharmaceutical industry segment that deals with the research, development, manufacturing, and distribution of drugs used in the treatment of cancer. Cancer is a complex and diverse disease, and numerous types of oncology drugs are developed to target different cancer types and stages.
Get More Information on Oncology Drugs Market - Request Sample Report
Chemotherapy drugs target rapidly dividing cancer cells and are commonly used in the treatment of various cancers. Immunotherapy type of treatment helps the body's immune system recognize and attack cancer cells. Targeted Therapy drugs specifically target certain molecules involved in cancer growth and progression. Hormone therapy is used to treat hormone-sensitive cancers, such as breast and prostate cancer. Biologic Therapies Include monoclonal antibodies and other biologically derived agents that target specific cancer cell components. Radiopharmaceuticals Drugs that carry radioactive elements, which can be used to target and destroy cancer cells.When cancer is detected early, it is more likely to react to appropriate therapy, resulting in a higher chance of survival, fewer morbidity, and less expensive treatment. The rise in the prevalence of cancer disease and the incidence of various cancer conditions, as well as an increase in the popularity of advanced therapies (biological and targeted drug therapies), are driving the growth of the oncology drugs market. Furthermore, the rise in cancer awareness and early cancer screening contributes to the growth of the oncology medications industry. The oncology drugs market is a significant and rapidly evolving sector within the pharmaceutical industry due to the increasing prevalence of cancer and ongoing research advancements. The market is influenced by factors such as the incidence of cancer cases, the introduction of new and innovative treatments, government regulations, and healthcare policies. It's important to note that the oncology drugs market may have evolved since my last update, and for the most current information, it is advisable to refer to recent industry reports and market analysis. However, the high costs associated with new drug development, as well as the risk of failure and bad effects associated with cancer treatment therapy, are limiting the expansion of the oncology pharmaceutical industry. Conversely, the high potential of emerging economies, as well as the increased number of prospective medications in the pipeline, are projected to provide profitable prospects throughout the projection period.
DRIVERS:
The increased global cancer prevalence has been a primary driver of the oncology medications industry.
The key driver of this industry is advancements in research and technology.
Ongoing advancements in medical research and technology have led to the discovery of new targets and pathways for cancer treatment. This has resulted in the development of innovative and targeted therapies that offer improved efficacy and reduced side effects compared to traditional treatments.
RESTRAIN:
The research and development process for oncology drugs is complex, time-consuming, and expensive.
The key constraint in this industry is the strict Regulatory Approval Process.
Oncology drugs are subject to rigorous testing and evaluation by regulatory authorities before they can be approved for use. The stringent approval process can be lengthy and uncertain, delaying the market entry of new drugs and increasing development costs.
OPPORTUNITY:
Advances in cancer research and genomics have led to the identification of specific molecular targets associated with different types of cancer.
The greatest opportunity in this sector is in combination therapies.
Combining different types of oncology drugs or using them alongside other treatment modalities like radiation or surgery has shown promising results. The opportunity lies in exploring and optimizing effective combination therapies to improve treatment outcomes.
CHALLENGES:
Developing oncology drugs is a complex and time-consuming process.
The main difficulty in this sector is drug pricing pressure.
The high prices of innovative oncology drugs can lead to pricing pressures from payers and health systems. Companies must navigate pricing strategies that balance affordability and maintain sustainable business models.
Since the Russian invasion began in 2022, more than 2.2-2.5 million refugees have fled Ukraine, and over 4.2-4.5 million people, or 12% of the population, are projected to be forcefully displaced as they seek safety, resulting in a wide-ranging humanitarian disaster. Ukraine has a significant cancer burden, with over 170 000 new cases expected in 2020. In addition, the country has one of the highest rates of childhood cancer mortality in the world. As a result, gaps in cancer care in Ukraine were already severe before Russia's unwarranted attack, and they have definitely grown as a result of the conflict.
According to WHO, at least 4.2 million Ukrainians are in need of health services, and those with cancer are especially susceptible if their treatment is disrupted by Russia's actions against the nation. To minimise life-threatening interruptions in cancer care, displaced patients must have continued access to oncology services regardless of whatever nation they eventually settle in. Maintaining continuity of treatment would be difficult, however, because many migrants may lack identity and current medical records. In this conflict, the oncology drugs market growth is up to 4-5% because of demand increases.
IMPACT OF ONGOING RECESSION
The public policy consensus in high-income nations is that the expenses of providing high-quality egalitarian cancer treatment pose a growing challenge to national budgets. Cancer care expenses in the United States alone are expected to reach 160 billion dollars by 2020. The rise is being driven by a number of causes, including technological advancement, increased medical and hospital care expenses, pricey treatments, and an increase in the proportion of people at risk of cancer as the population ages. This article examines the elements that shape and influence the political discussion on cancer economics in Europe and North America. In the ongoing recession, the Oncology Drugs Market growth is increased by the rate of 2-3% because the number of cancer patients is also increasing.
By Drugs Class
Targeted Drugs
Hormonal Drugs
Others
By Therapy
Chemotherapy
Targeted Therapy
Immunotherapy
By Indication
Prostate Cancer
Colorectal Cancer
By Dosage Form
Liquid
Solid
By Distribution Channel
Retail Pharmacies
Hospital Pharmacies
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
REGIONAL ANALYSIS
North America: The Oncology Drugs Market will be dominated by North America (the United States, Canada, and Mexico). The rising frequency of cancer patients among the demography, as well as the expanding penetration of top players in the United States and Canada, are the primary factors driving market expansion in the North American area. Because of the growing prevalence of cancer, good healthcare facilities, and the presence of significant industry players in the area, the United States is likely to have the dominating share of the market in the North American region.
Asia Pacific: During the forecast period, the Asia Pacific region (India, Japan, China, Malaysia, Singapore, & the Rest of Asia Pacific) is predicted to be the fastest-growing sector in the Oncology Drugs Market. Some of the market's drivers include the fast-growing elderly population and the increased need for enhanced healthcare facilities, particularly in emerging nations in the area. The existence of large pharmaceutical industries such as India and China would also help to drive regional market expansion. China is predicted to dominate the APAC market due to increased government expenditure on enhancing healthcare facilities in the area, as well as the government's aim to promote the domestic manufacture of high-quality medicines.
Get More Information on Oncology Drugs Market - Enquiry Now
Some major players in Oncology Drugs Market are Genentech, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, AstraZeneca, Eli Lilly & Company, Bayer AG, Sanofi and other players.
In 2021: Bayer, a German multinational pharmaceutical and biotechnology firm, bought Noria, a radiotherapy company, and PSMA Therapeutics, a Noria subsidiary, to boost its prostate cancer product pipeline. Bayer was granted exclusive rights to develop an alpha radionuclide investigational drug based on actinium-225 with a small molecule directed against prostate-specific membrane antigen (PSMA) under this deal.
In 2020: Aichi Cancer Centre and NEC Corporation, a multinational information technology and electronics corporation headquartered in Japan, announced the launch of fundamental research aimed at realising the world of advanced personalised cancer immunotherapy by improving the performance of NEC's neoantigen prediction system and developing predictive biomarkers for patient stratification via the fusion of artificial intelligence and experimental immunology.
| Report Attributes | Details |
| Market Size in 2023 | US$ 221.38 Bn |
| Market Size by 2031 | US$ 525.08 Bn |
| CAGR | CAGR of 11.4% From 2024 to 2031 |
| Base Year | 2023 |
| Forecast Period | 2024-2031 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drugs Class (Targeted Drugs, Cytotoxic Drugs, Hormonal Drugs, Others) • By Therapy (Chemotherapy, Targeted Therapy, Immunotherapy) • By Indication (Stomach Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer) • By Dosage Form (Liquid, Solid) • By Distribution Channel (Retail Pharmacies, Hospital Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]). Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
| Company Profiles | Genentech, Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, AstraZeneca, Eli Lilly & Company, Bayer AG, Sanofi |
| Key Drivers | • The increased global cancer prevalence has been a primary driver of the oncology medications industry. • The key driver of this industry is advancements in research and technology. |
| Market Restraints | • The research and development process for oncology drugs is complex, time-consuming, and expensive. • The key constraint in this industry is the strict Regulatory Approval Process. |
Ans. The Oncology Drugs Market is to grow at a CAGR of 11.4% Over the Forecast Period of 2024-2031.
Ans. By 2031, the market for Bovine Mastitis is expected to be worth USD 525.08 Billion.
Ans. The North American market was worth USD 221.38 billion in 2023.
Ans. The rising frequency of malignancies, as well as the existence of excellent pipeline prospects, are important drivers driving market expansion.
Ans. During the projected period, the targeted drug segment is likely to be the market's leading sector by drug class.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope
1.3 Research Assumptions
2. Research Methodology
3. Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
4. Impact Analysis
4.1 Impact of Russia-Ukraine War
4.2 Impact of Ongoing Recession
4.2.1 Introduction
4.2.2 Impact on major economies
4.2.2.1 US
4.2.2.2 Canada
4.2.2.3 Germany
4.2.2.4 France
4.2.2.5 United Kingdom
4.2.2.6 China
4.2.2.7 Japan
4.2.2.8 South Korea
4.2.2.9 Rest of the World
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Oncology Drugs Market Segmentation, By Drugs Class
8.1 Targeted Drugs
8.2 Cytotoxic Drugs
8.3 Hormonal Drugs
8.4 Others
9. Oncology Drugs Market Segmentation, By Therapy
9.1 Chemotherapy
9.2 Targeted Therapy
9.3 Immunotherapy
10. Oncology Drugs Market Segmentation, By Indication
10.1 Stomach Cancer
10.2 Lung Cancer
10.3 Prostate Cancer
10.4 Colorectal Cancer
10.5 Breast Cancer
11. Oncology Drugs Market Segmentation, By Dosage Form
11.1 Liquid
11.2 Solid
12. Oncology Drugs Market Segmentation, By Distribution Channel
12.1 Retail Pharmacies
12.2 Hospital Pharmacies
13. Regional Analysis
13.1 Introduction
13.2 North America
13.2.1 North America Oncology Drugs Market by Country
13.2.2 North America Oncology Drugs Market by Drugs Class
13.2.3 North America Oncology Drugs Market by Therapy
13.2.4 North America Oncology Drugs Market by Indication
13.2.5 North America Oncology Drugs Market by Dosage Form
13.2.6 North America Oncology Drugs Market by Distribution Channel
13.2.7 USA
13.2.7.1 USA Oncology Drugs Market by Drugs Class
13.2.7.2 USA Oncology Drugs Market by Therapy
13.2.7.3 USA Oncology Drugs Market by Indication
13.2.7.4 USA Oncology Drugs Market by Dosage Form
13.2.7.5 USA Oncology Drugs Market by Distribution Channel
13.2.8 Canada
13.2.8.1 Canada Oncology Drugs Market by Drugs Class
13.2.8.2 Canada Oncology Drugs Market by Therapy
13.2.8.3 Canada Oncology Drugs Market by Indication
13.2.8.4 Canada Oncology Drugs Market by Dosage Form
13.2.8.5 Canada Oncology Drugs Market by Distribution Channel
13.2.9 Mexico
13.2.9.1 Mexico Oncology Drugs Market by Drugs Class
13.2.9.2 Mexico Oncology Drugs Market by Therapy
13.2.9.3 Mexico Oncology Drugs Market by Indication
13.2.9.4 Mexico Oncology Drugs Market by Dosage Form
13.2.9.5 Mexico Oncology Drugs Market by Distribution Channel
13.3 Europe
13.3.1 Eastern Europe
13.3.1.1 Eastern Europe Oncology Drugs Market by Country
13.3.1.2 Eastern Europe Oncology Drugs Market by Drugs Class
13.3.1.3 Eastern Europe Oncology Drugs Market by Therapy
13.3.1.4 Eastern Europe Oncology Drugs Market by Indication
13.3.1.5 Eastern Europe Oncology Drugs Market by Dosage Form
13.3.1.6 Eastern Europe Oncology Drugs Market by Distribution Channel
13.3.1.7 Poland
13.3.1.7.1 Poland Oncology Drugs Market by Drugs Class
13.3.1.7.2 Poland Oncology Drugs Market by Therapy
13.3.1.7.3 Poland Oncology Drugs Market by Indication
13.3.1.7.4 Poland Oncology Drugs Market by Dosage Form
13.3.1.7.5 Poland Oncology Drugs Market by Distribution Channel
13.3.1.8 Romania
13.3.1.8.1 Romania Oncology Drugs Market by Drugs Class
13.3.1.8.2 Romania Oncology Drugs Market by Therapy
13.3.1.8.3 Romania Oncology Drugs Market by Indication
13.3.1.8.4 Romania Oncology Drugs Market by Dosage Form
13.3.1.8.5 Romania Oncology Drugs Market by Distribution Channel
13.3.1.9 Hungary
13.3.1.9.1 Hungary Oncology Drugs Market by Drugs Class
13.3.1.9.2 Hungary Oncology Drugs Market by Therapy
13.3.1.9.3 Hungary Oncology Drugs Market by Indication
13.3.1.9.4 Hungary Oncology Drugs Market by Dosage Form
13.3.1.9.5 Hungary Oncology Drugs Market by Distribution Channel
13.3.1.10 Turkey
13.3.1.10.1 Turkey Oncology Drugs Market by Drugs Class
13.3.1.10.2 Turkey Oncology Drugs Market by Therapy
13.3.1.10.3 Turkey Oncology Drugs Market by Indication
13.3.1.10.4 Turkey Oncology Drugs Market by Dosage Form
13.3.1.10.5 Turkey Oncology Drugs Market by Distribution Channel
13.3.1.11 Rest of Eastern Europe
13.3.1.11.1 Rest of Eastern Europe Oncology Drugs Market by Drugs Class
13.3.1.11.2 Rest of Eastern Europe Oncology Drugs Market by Therapy
13.3.1.11.3 Rest of Eastern Europe Oncology Drugs Market by Indication
13.3.1.11.4 Rest of Eastern Europe Oncology Drugs Market by Dosage Form
13.3.1.11.5 Rest of Eastern Europe Oncology Drugs Market by Distribution Channel
13.3.2 Western Europe
13.3.2.1 Western Europe Oncology Drugs Market by Country
13.3.2.2 Western Europe Oncology Drugs Market by Drugs Class
13.3.2.3 Western Europe Oncology Drugs Market by Therapy
13.3.2.4 Western Europe Oncology Drugs Market by Indication
13.3.2.5 Western Europe Oncology Drugs Market by Dosage Form
13.3.2.6 Western Europe Oncology Drugs Market by Distribution Channel
13.3.2.7 Germany
13.3.2.7.1 Germany Oncology Drugs Market by Drugs Class
13.3.2.7.2 Germany Oncology Drugs Market by Therapy
13.3.2.7.3 Germany Oncology Drugs Market by Indication
13.3.2.7.4 Germany Oncology Drugs Market by Dosage Form
13.3.2.7.5 Germany Oncology Drugs Market by Distribution Channel
13.3.2.8 France
13.3.2.8.1 France Oncology Drugs Market by Drugs Class
13.3.2.8.2 France Oncology Drugs Market by Therapy
13.3.2.8.3 France Oncology Drugs Market by Indication
13.3.2.8.4 France Oncology Drugs Market by Dosage Form
13.3.2.8.5 France Oncology Drugs Market by Distribution Channel
13.3.2.9 UK
13.3.2.9.1 UK Oncology Drugs Market by Drugs Class
13.3.2.9.2 UK Oncology Drugs Market by Therapy
13.3.2.9.3 UK Oncology Drugs Market by Indication
13.3.2.9.4 UK Oncology Drugs Market by Dosage Form
13.3.2.9.5 UK Oncology Drugs Market by Distribution Channel
13.3.2.10 Italy
13.3.2.10.1 Italy Oncology Drugs Market by Drugs Class
13.3.2.10.2 Italy Oncology Drugs Market by Therapy
13.3.2.10.3 Italy Oncology Drugs Market by Indication
13.3.2.10.4 Italy Oncology Drugs Market by Dosage Form
13.3.2.10.5 Italy Oncology Drugs Market by Distribution Channel
13.3.2.11 Spain
13.3.2.11.1 Spain Oncology Drugs Market by Drugs Class
13.3.2.11.2 Spain Oncology Drugs Market by Therapy
13.3.2.11.3 Spain Oncology Drugs Market by Indication
13.3.2.11.4 Spain Oncology Drugs Market by Dosage Form
13.3.2.11.5 Spain Oncology Drugs Market by Distribution Channel
13.3.2.12 The Netherlands
13.3.2.12.1 Netherlands Oncology Drugs Market by Drugs Class
13.3.2.12.2 Netherlands Oncology Drugs Market by Therapy
13.3.2.12.3 Netherlands Oncology Drugs Market by Indication
13.3.2.12.4 Netherlands Oncology Drugs Market by Dosage Form
13.3.2.12.5 Netherlands Oncology Drugs Market by Distribution Channel
13.3.2.13 Switzerland
13.3.2.13.1 Switzerland Oncology Drugs Market by Drugs Class
13.3.2.13.2 Switzerland Oncology Drugs Market by Therapy
13.3.2.13.3 Switzerland Oncology Drugs Market by Indication
13.3.2.13.4 Switzerland Oncology Drugs Market by Dosage Form
13.3.2.13.5 Switzerland Oncology Drugs Market by Distribution Channel
13.3.2.14 Austria
13.3.2.14.1 Austria Oncology Drugs Market by Drugs Class
13.3.2.14.2 Austria Oncology Drugs Market by Therapy
13.3.2.14.3 Austria Oncology Drugs Market by Indication
13.3.2.14.4 Austria Oncology Drugs Market by Dosage Form
13.3.2.14.5 Austria Oncology Drugs Market by Distribution Channel
13.3.2.15 Rest of Western Europe
13.3.2.15.1 Rest of Western Europe Oncology Drugs Market by Drugs Class
13.3.2.15.2 Rest of Western Europe Oncology Drugs Market by Therapy
13.3.2.15.3 Rest of Western Europe Oncology Drugs Market by Indication
13.3.2.15.4 Rest of Western Europe Oncology Drugs Market by Dosage Form
13.3.2.15.5 Rest of Western Europe Oncology Drugs Market by Distribution Channel
13.4 Asia-Pacific
13.4.1 Asia Pacific Oncology Drugs Market by Country
13.4.2 Asia Pacific Oncology Drugs Market by Drugs Class
13.4.3 Asia Pacific Oncology Drugs Market by Therapy
13.4.4 Asia Pacific Oncology Drugs Market by Indication
13.4.5 Asia Pacific Oncology Drugs Market by Dosage Form
13.4.6 Asia Pacific Oncology Drugs Market by Distribution Channel
13.4.7 China
13.4.7.1 China Oncology Drugs Market by Drugs Class
13.4.7.2 China Oncology Drugs Market by Therapy
13.4.7.3 China Oncology Drugs Market by Indication
13.4.7.4 China Oncology Drugs Market by Dosage Form
13.4.7.5 China Oncology Drugs Market by Distribution Channel
13.4.8 India
13.4.8.1 India Oncology Drugs Market by Drugs Class
13.4.8.2 India Oncology Drugs Market by Therapy
13.4.8.3 India Oncology Drugs Market by Indication
13.4.8.4 India Oncology Drugs Market by Dosage Form
13.4.8.5 India Oncology Drugs Market by Distribution Channel
13.4.9 Japan
13.4.9.1 Japan Oncology Drugs Market by Drugs Class
13.4.9.2 Japan Oncology Drugs Market by Therapy
13.4.9.3 Japan Oncology Drugs Market by Indication
13.4.9.4 Japan Oncology Drugs Market by Dosage Form
13.4.9.5 Japan Oncology Drugs Market by Distribution Channel
13.4.10 South Korea
13.4.10.1 South Korea Oncology Drugs Market by Drugs Class
13.4.10.2 South Korea Oncology Drugs Market by Therapy
13.4.10.3 South Korea Oncology Drugs Market by Indication
13.4.10.4 South Korea Oncology Drugs Market by Dosage Form
13.4.10.5 South Korea Oncology Drugs Market by Distribution Channel
13.4.11 Vietnam
13.4.11.1 Vietnam Oncology Drugs Market by Drugs Class
13.4.11.2 Vietnam Oncology Drugs Market by Therapy
13.4.11.3 Vietnam Oncology Drugs Market by Indication
13.4.11.4 Vietnam Oncology Drugs Market by Dosage Form
13.4.11.5 Vietnam Oncology Drugs Market by Distribution Channel
13.4.12 Singapore
13.4.12.1 Singapore Oncology Drugs Market by Drugs Class
13.4.12.2 Singapore Oncology Drugs Market by Therapy
13.4.12.3 Singapore Oncology Drugs Market by Indication
13.4.12.4 Singapore Oncology Drugs Market by Dosage Form
13.4.12.5 Singapore Oncology Drugs Market by Distribution Channel
13.4.13 Australia
13.4.13.1 Australia Oncology Drugs Market by Drugs Class
13.4.13.2 Australia Oncology Drugs Market by Therapy
13.4.13.3 Australia Oncology Drugs Market by Indication
13.4.13.4 Australia Oncology Drugs Market by Dosage Form
13.4.13.5 Australia Oncology Drugs Market by Distribution Channel
13.4.14 Rest of Asia-Pacific
13.4.14.1 APAC Oncology Drugs Market by Drugs Class
13.4.14.2 APAC Oncology Drugs Market by Therapy
13.4.14.3 APAC Oncology Drugs Market by Indication
13.4.14.4 APAC Oncology Drugs Market by Dosage Form
13.4.14.5 APAC Oncology Drugs Market by Distribution Channel
13.5 The Middle East & Africa
13.5.1 Middle East
13.5.1.1 Middle East Oncology Drugs Market by Country
13.5.1.2 Middle East Oncology Drugs Market by Drugs Class
13.5.1.3 Middle East Oncology Drugs Market by Therapy
13.5.1.4 Middle East Oncology Drugs Market by Indication
13.5.1.5 Middle East Oncology Drugs Market by Dosage Form
13.5.1.6 Middle East Oncology Drugs Market by Distribution Channel
13.5.1.7 UAE
13.5.1.7.1 UAE Oncology Drugs Market by Drugs Class
13.5.1.7.2 UAE Oncology Drugs Market by Therapy
13.5.1.7.3 UAE Oncology Drugs Market by Indication
13.5.1.7.4 UAE Oncology Drugs Market by Dosage Form
13.5.1.7.5 UAE Oncology Drugs Market by Distribution Channel
13.5.1.8 Egypt
13.5.1.8.1 Egypt Oncology Drugs Market by Drugs Class
13.5.1.8.2 Egypt Oncology Drugs Market by Therapy
13.5.1.8.3 Egypt Oncology Drugs Market by Indication
13.5.1.8.4 Egypt Oncology Drugs Market by Dosage Form
13.5.1.8.5 Egypt Oncology Drugs Market by Distribution Channel
13.5.1.9 Saudi Arabia
13.5.1.9.1 Saudi Arabia Oncology Drugs Market by Drugs Class
13.5.1.9.2 Saudi Arabia Oncology Drugs Market by Therapy
13.5.1.9.3 Saudi Arabia Oncology Drugs Market by Indication
13.5.1.9.4 Saudi Arabia Oncology Drugs Market by Dosage Form
13.5.1.9.5 Saudi Arabia Oncology Drugs Market by Distribution Channel
13.5.1.10 Qatar
13.5.1.10.1 Qatar Oncology Drugs Market by Drugs Class
13.5.1.10.2 Qatar Oncology Drugs Market by Therapy
13.5.1.10.3 Qatar Oncology Drugs Market by Indication
13.5.1.10.4 Qatar Oncology Drugs Market by Dosage Form
13.5.1.10.5 Qatar Oncology Drugs Market by Distribution Channel
13.5.1.11 Rest of Middle East
13.5.1.11.1 Rest of Middle East Oncology Drugs Market by Drugs Class
13.5.1.11.2 Rest of Middle East Oncology Drugs Market by Therapy
13.5.1.11.3 Rest of Middle East Oncology Drugs Market by Indication
13.5.1.11.4 Rest of Middle East Oncology Drugs Market by Dosage Form
13.5.1.11.5 Rest of Middle East Oncology Drugs Market by Distribution Channel
13.5.2 Africa
13.5.2.1 Africa Oncology Drugs Market by Country
13.5.2.2 Africa Oncology Drugs Market by Drugs Class
13.5.2.3 Africa Oncology Drugs Market by Therapy
13.5.2.4 Africa Oncology Drugs Market by Indication
13.5.2.5 Africa Oncology Drugs Market by Dosage Form
13.5.2.6 Africa Oncology Drugs Market by Distribution Channel
13.5.2.7 Nigeria
13.5.2.7.1 Nigeria Oncology Drugs Market by Drugs Class
13.5.2.7.2 Nigeria Oncology Drugs Market by Therapy
13.5.2.7.3 Nigeria Oncology Drugs Market by Indication
13.5.2.7.4 Nigeria Oncology Drugs Market by Dosage Form
13.5.2.7.5 Nigeria Oncology Drugs Market by Distribution Channel
13.5.2.8 South Africa
13.5.2.8.1 South Africa Oncology Drugs Market by Drugs Class
13.5.2.8.2 South Africa Oncology Drugs Market by Therapy
13.5.2.8.3 South Africa Oncology Drugs Market by Indication
13.5.2.8.4 South Africa Oncology Drugs Market by Dosage Form
13.5.2.8.5 South Africa Oncology Drugs Market by Distribution Channel
13.5.2.9 Rest of Africa
13.5.2.9.1 Rest of Africa Oncology Drugs Market by Drugs Class
13.5.2.9.2 Rest of Africa Oncology Drugs Market by Therapy
13.5.2.9.3 Rest of Africa Oncology Drugs Market by Indication
13.5.2.9.4 Rest of Africa Oncology Drugs Market by Dosage Form
13.5.2.9.5 Rest of Africa Oncology Drugs Market by Distribution Channel
13.6 Latin America
13.6.1 Latin America Oncology Drugs Market by Country
13.6.2 Latin America Oncology Drugs Market by Drugs Class
13.6.3 Latin America Oncology Drugs Market by Therapy
13.6.4 Latin America Oncology Drugs Market by Indication
13.6.5 Latin America Oncology Drugs Market by Dosage Form
13.6.6 Latin America Oncology Drugs Market by Distribution Channel
13.6.7 Brazil
13.6.7.1 Brazil Oncology Drugs Market by Drugs Class
13.6.7.2 Brazil Oncology Drugs Market by Therapy
13.6.7.3 Brazil Oncology Drugs Market by Indication
13.6.7.4 Brazil Oncology Drugs Market by Dosage Form
13.6.7.5 Brazil Oncology Drugs Market by Distribution Channel
13.6.8 Argentina
13.6.8.1 Argentina Oncology Drugs Market by Drugs Class
13.6.8.2 Argentina Oncology Drugs Market by Therapy
13.6.8.3 Argentina Oncology Drugs Market by Indication
13.6.8.4 Argentina Oncology Drugs Market by Dosage Form
13.6.8.5 Argentina Oncology Drugs Market by Distribution Channel
13.6.9 Colombia
13.6.9.1 Colombia Oncology Drugs Market by Drugs Class
13.6.9.2 Colombia Oncology Drugs Market by Therapy
13.6.9.3 Colombia Oncology Drugs Market by Indication
13.6.9.4 Colombia Oncology Drugs Market by Dosage Form
13.6.9.5 Colombia Oncology Drugs Market by Distribution Channel
13.6.10 Rest of Latin America
13.6.10.1 Rest of Latin America Oncology Drugs Market by Drugs Class
13.6.10.2 Rest of Latin America Oncology Drugs Market by Therapy
13.6.10.3 Rest of Latin America Oncology Drugs Market by Indication
13.6.10.4 Rest of Latin America Oncology Drugs Market by Dosage Form
13.6.10.5 Rest of Latin America Oncology Drugs Market by Distribution Channel
14 Company Profile
14.1 Genentech, Inc.,
14.1.1 Company Overview
14.1.2 Financials
14.1.3 Product/Services Offered
14.1.4 SWOT Analysis
14.1.5 The SNS View
14.2 F. Hoffmann-La Roche Ltd
14.2.1 Company Overview
14.2.2 Financials
14.2.3 Product/Services Offered
14.2.4 SWOT Analysis
14.2.5 The SNS View
14.3 Novartis AG
14.3.1 Company Overview
14.3.2 Financials
14.3.3 Product/Services Offered
14.3.4 SWOT Analysis
14.3.5 The SNS View
14.4 Pfizer Inc
14.4.1 Company Overview
14.4.2 Financials
14.4.3 Product/Services Offered
14.4.4 SWOT Analysis
14.4.5 The SNS View
14.5 GlaxoSmithKline plc
14.5.1 Company Overview
14.5.2 Financials
14.5.3 Product/Services Offered
14.5.4 SWOT Analysis
14.5.5 The SNS View
14.6 Bristol-Myers Squibb Company
14.6.1 Company Overview
14.6.2 Financials
14.6.3 Product/Services Offered
14.6.4 SWOT Analysis
14.6.5 The SNS View
14.7 AstraZeneca
14.7.1 Company Overview
14.7.2 Financials
14.7.3 Product/Services Offered
14.7.4 SWOT Analysis
14.7.5 The SNS View
14.8 Eli Lilly & Company
14.8.1 Company Overview
14.8.2 Financials
14.8.3 Product/Services Offered
14.8.4 SWOT Analysis
14.8.5 The SNS View
14.9 Bayer AG
14.9.1 Company Overview
14.9.2 Financials
14.9.3 Product/Services Offered
14.9.4 SWOT Analysis
14.9.5 The SNS View
14.10 Sanofi
14.10.1 Company Overview
14.10.2 Financials
14.10.3 Product/Services Offered
14.10.4 SWOT Analysis
14.10.5 The SNS View
15. Competitive Landscape
15.1 Competitive Benchmarking
15.2 Market Share Analysis
15.3 Recent Developments
15.3.1 Industry News
15.3.2 Company News
15.3.3 Mergers & Acquisitions
16. USE Cases and Best Practices
17. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
The Nebulizer Market Size was estimated at USD 1.16 billion in 2023 and is poised to reach 2.05 billion in 2032 at a CAGR of 6.57% by 2024-2031.
The Nucleic Acid Isolation and Purification Market Size was valued at USD 6.60 Billion in 2023 and is expected to reach USD 16.38 Billion by 2032 and grow at a CAGR of 11.18% over the forecast period 2024-2032.
The Ultrasound Probe Disinfection Market size was estimated at USD 573.04 million in 2023 and is expected to reach USD 1819.84 million by 2032 with a growing CAGR of 13.7% during the forecast period of 2024-2032.
The IVD (In Vitro Diagnostics) Market size was valued at USD 83.04 billion in 2023 and is estimated to reach USD 126.6 billion by 2032, with a growing CAGR of 4.8% over the forecast period 2024-2032.
The Life Science Analytics Market Size was USD 9.89 Bn in 2023 and is expected to reach at USD 20.0 Bn by 2032, and develop at a CAGR of 7.61% by 2024-2032
The Population Health Management Market Size was valued USD 71.83 Bn in 2023, & will reach USD 352.55 Bn by 2031, and grow at a CAGR of 22.07% by 2024-2031.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
